BCRX or GILD or MNKD
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green whileGILD’s FA Score has 2 green FA rating(s), and MNKD’s FA Score reflects 0 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- GILD’s FA Score: 2 green, 3 red.
- MNKD’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 6 TA indicator(s) are bullish while GILD’s TA Score has 5 bullish TA indicator(s), and MNKD’s TA Score reflects 5 bullish TA indicator(s).
- BCRX’s TA Score: 6 bullish, 3 bearish.
- GILD’s TA Score: 5 bullish, 5 bearish.
- MNKD’s TA Score: 5 bullish, 3 bearish.
Price Growth
BCRX (@Biotechnology) experienced а +11.08% price change this week, while GILD (@Pharmaceuticals: Major) price change was +1.54% , and MNKD (@Biotechnology) price fluctuated +2.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.16%. For the same industry, the average monthly price growth was -2.53%, and the average quarterly price growth was -8.74%.
Reported Earning Dates
BCRX is expected to report earnings on Jul 31, 2025.
GILD is expected to report earnings on Aug 05, 2025.
MNKD is expected to report earnings on Aug 06, 2025.
Industries' Descriptions
@Biotechnology (+7.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+2.16% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BCRX | GILD | MNKD | |
| Capitalization | 1.72B | 90.8B | 1.42B |
| EBITDA | 12.8M | 10.5B | 77.5M |
| Gain YTD | 9.309 | 15.725 | -27.372 |
| P/E Ratio | N/A | 16.20 | 46.70 |
| Revenue | 451M | 27.1B | 286M |
| Total Cash | 321M | 7.26B | 197M |
| Total Debt | 809M | 25B | 47.7M |
BCRX | GILD | MNKD | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 71 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 34 Fair valued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 65 | 16 | 37 | |
SMR RATING 1..100 | 100 | 88 | 100 | |
PRICE GROWTH RATING 1..100 | 42 | 40 | 63 | |
P/E GROWTH RATING 1..100 | 100 | 1 | 96 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (31) in the Biotechnology industry is in the same range as GILD (34) and is in the same range as MNKD (60). This means that BCRX's stock grew similarly to GILD’s and similarly to MNKD’s over the last 12 months.
GILD's Profit vs Risk Rating (16) in the Biotechnology industry is in the same range as MNKD (37) and is somewhat better than the same rating for BCRX (65). This means that GILD's stock grew similarly to MNKD’s and somewhat faster than BCRX’s over the last 12 months.
GILD's SMR Rating (88) in the Biotechnology industry is in the same range as MNKD (100) and is in the same range as BCRX (100). This means that GILD's stock grew similarly to MNKD’s and similarly to BCRX’s over the last 12 months.
GILD's Price Growth Rating (40) in the Biotechnology industry is in the same range as BCRX (42) and is in the same range as MNKD (63). This means that GILD's stock grew similarly to BCRX’s and similarly to MNKD’s over the last 12 months.
GILD's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for MNKD (96) and is significantly better than the same rating for BCRX (100). This means that GILD's stock grew significantly faster than MNKD’s and significantly faster than BCRX’s over the last 12 months.
| BCRX | GILD | MNKD | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 55% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 47% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 60% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 63% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 55% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 48% | 2 days ago 75% |
| Advances ODDS (%) | 2 days ago 79% | 3 days ago 58% | 2 days ago 82% |
| Declines ODDS (%) | 18 days ago 80% | 5 days ago 49% | 18 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 52% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 51% | 2 days ago 72% |
MNKD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To MNKD | 1D Price Change % | ||
|---|---|---|---|---|
| MNKD | 100% | +1.30% | ||
| VCYT - MNKD | 44% Loosely correlated | +2.15% | ||
| LXRX - MNKD | 42% Loosely correlated | +4.70% | ||
| INSM - MNKD | 40% Loosely correlated | -2.60% | ||
| BLUE - MNKD | 38% Loosely correlated | +1.71% | ||
| AMRN - MNKD | 36% Loosely correlated | +7.92% | ||
More | ||||